RT Journal Article
T1 A novel hemocompatible core@shell nanosystem for selective targeting and apoptosis induction in cancer cells.
A1 Aragoneses Cazorla, Guillermo
A1 Serrano López, Juana
A1 Martínez Alfonzo, Inés
A1 Vallet Regí, María Dulce Nombre
A1 González Ortiz, Blanca
A1 Luque-García, José L.
AB One of the main problems with drug-based cancer treatments is the lack of selectivity, which causes them to be distributed non-specifically in the body and cells, generating undesirable side effects. In this work, a novel hybrid nanosystem for cancer cell targeting and therapeutic delivery of Ag nanoparticles has been designed. The proposed nanosystem contains a Ag core coated with a mesoporous silica shell which prevents the aggregation of Ag nanoparticles and allows the anchoring of transferrin as a targeting ligand, thus enabling the nanosystem to be selectively directed to cancer cells that overexpress transferrin receptors. The analytical and functional characterization of the nanosystem has allowed to demonstrate selective internalization and its cytotoxic potential in cancer cells where it induces apoptosis. Additional bioanalytical experiments have enabled the identification of different transcripts and altered proteins in cells treated with the nanosystem, which has made it possible to delve deeper into the biomolecular mechanisms by which the nanosystem exerts its action. Furthermore, a hemocompatibility study indicates neither activation of monocytes nor platelet aggregation after nanosystem exposure, hence supporting the future clinical applicability of the Ag@MSNs-Tf nanosystem.
PB Royal Society of Chemistry
SN 2052-1553
YR 2021
FD 2021-03-10
LK https://hdl.handle.net/20.500.14352/8228
UL https://hdl.handle.net/20.500.14352/8228
LA eng
NO RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)RESEARCHER ID K-4773-2015 (Blanca González Ortiz)ORCID 0000-0002-0493-6071 (Blanca González Ortiz)
NO Unión Europea. Horizonte 2020
NO Ministerio de Economía y Competitividad (MINECO)
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 3 may 2024